-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Extends BARDA Ebola Treatment Supply Deal, Adding About $270 Million

PUBT·10/26/2026 11:08:30
Listen to the news
Regeneron Extends BARDA Ebola Treatment Supply Deal, Adding About $270 Million
  • Regeneron Pharmaceuticals extended its BARDA agreement to supply additional doses of Ebola treatment Inmazeb for U.S. preparedness.
  • The extension adds approximately $270 million to the 2020 procurement agreement, with deliveries to the U.S. government expected through 2031.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852299) on October 26, 2026, and is solely responsible for the information contained therein.